Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Amryt Pharma
The once-daily oral somatostatin receptor type 2 (SST2) agonist outshined placebo in patients switching from standard of care, offering an attractive alternative to once-monthly injectables.
Chiesi-owned Amryt and Krystal Biotech have approved treatments for epidermolysis bullosa but Paradigm CEO Robert Ryan tells Scrip that SD-101, a topical cream he helped develop over 20 years ago, has the potential to be offer a far more extensive and efficacious solution for many more sufferers.
Amryt’s Filsuvez Wins English Funding For Butterfly Skin Disease, Sanofi’s Dupixent Rejected In New Indication
Amryt/Chiesi’s birch bark extract gel, Filsuvez, is the first ever treatment for epidermolysis bullosa, a group of rare skin disorders, to be recommended by NICE for English reimbursement.
Oncology's surprisingly low numbers this year are among the latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
- Specialty Pharmaceuticals
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.